Treatment of PTEN-deficient glioma cells with a cell-penetrating antibody against RAD51, 3E10, leads to an accumulation of DNA damage causing decreased proliferation and increased cell death compared to isogenic PTEN-proficient controls [185]. Here, PTEN is linked to glioma.